AZTR (Azitra) Cash-to-Debt : 8.21 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Azitra Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Azitra's cash to debt ratio for the quarter that ended in Dec. 2024 was 8.21.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Azitra could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Azitra's Cash-to-Debt or its related term are showing as below:

AZTR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.45 Med: 5.07 Max: 8.21
Current: 8.21

During the past 4 years, Azitra's highest Cash to Debt Ratio was 8.21. The lowest was 0.45. And the median was 5.07.

AZTR's Cash-to-Debt is ranked better than
51.31% of 1485 companies
in the Biotechnology industry
Industry Median: 7.49 vs AZTR: 8.21

Azitra Cash-to-Debt Historical Data

The historical data trend for Azitra's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Azitra Cash-to-Debt Chart

Azitra Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

8.11

0.45

2.03

8.21

Azitra Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial								2.03	3.73	1.11	11.27	8.21

Competitive Comparison of Azitra's Cash-to-Debt

For the Biotechnology subindustry, Azitra's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Azitra's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Azitra's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Azitra's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Azitra Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Azitra's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.555	/	(0.271	+	0.284)
	=	8.21

Azitra's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.555	/	(0.271	+	0.284)
	=	8.21

Azitra (AMEX:AZTR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Azitra Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Azitra's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Azitra Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Azitra Inc (AMEX:AZTR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Business Park Drive, Branford, CT, USA, 06405

Website

https://www.azitrainc.com

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Executives

Norm Staskey	officer: Chief Financial Officer	21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Francisco D. Salva	director, officer: President and CEO	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Travis Whitfill	director, officer: Chief Operating Officer	C/O IN8BIO,INC., 79 MADISON AVENUE, NEW YORK NY 10016
Fletcher Aaron G.l.	10 percent owner	40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Andrew Mcclary	director	21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Aktiengesellschaft Bayer	10 percent owner	BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Bios Azitra Co-invest I, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bayer Us Holding Lp	10 percent owner	100 BAYER BOULEVARD, WHIPPANY NJ 07981
Bayer Healthcare Llc	10 percent owner
Bios Equity Partners Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107